AU2006206652A1 - Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido(3,4- d) pyrimidines as inhibitors of mitotic kinesins - Google Patents

Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido(3,4- d) pyrimidines as inhibitors of mitotic kinesins Download PDF

Info

Publication number
AU2006206652A1
AU2006206652A1 AU2006206652A AU2006206652A AU2006206652A1 AU 2006206652 A1 AU2006206652 A1 AU 2006206652A1 AU 2006206652 A AU2006206652 A AU 2006206652A AU 2006206652 A AU2006206652 A AU 2006206652A AU 2006206652 A1 AU2006206652 A1 AU 2006206652A1
Authority
AU
Australia
Prior art keywords
alkyl
cycloalkyl
compound
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006206652A
Other languages
English (en)
Inventor
Paul J. Coleman
George D. Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp & Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2006206652A1 publication Critical patent/AU2006206652A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK & CO., INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006206652A 2005-01-19 2006-01-13 Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido(3,4- d) pyrimidines as inhibitors of mitotic kinesins Abandoned AU2006206652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64490705P 2005-01-19 2005-01-19
US60/644,907 2005-01-19
PCT/US2006/001365 WO2006078575A2 (en) 2005-01-19 2006-01-13 Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido[3,4- d] pyrimidines as inhibitors of mitotic kinesins

Publications (1)

Publication Number Publication Date
AU2006206652A1 true AU2006206652A1 (en) 2006-07-27

Family

ID=36692759

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006206652A Abandoned AU2006206652A1 (en) 2005-01-19 2006-01-13 Fluorinated aminoalkyl-4-oxo-3,4-dihydropyrido(3,4- d) pyrimidines as inhibitors of mitotic kinesins

Country Status (7)

Country Link
US (1) US7632839B2 (cg-RX-API-DMAC7.html)
EP (1) EP1855664A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008527039A (cg-RX-API-DMAC7.html)
CN (1) CN101193637A (cg-RX-API-DMAC7.html)
AU (1) AU2006206652A1 (cg-RX-API-DMAC7.html)
CA (1) CA2595130A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006078575A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346988B1 (en) * 2008-10-31 2017-05-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
UY32922A (es) * 2009-10-06 2011-04-29 Bayer Schering Pharma Ag Derivados de 3, 5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103575A2 (en) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005530806A (ja) * 2002-05-23 2005-10-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害薬
WO2005046588A2 (en) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
CN101193637A (zh) 2008-06-04
CA2595130A1 (en) 2006-07-27
US20080139586A1 (en) 2008-06-12
US7632839B2 (en) 2009-12-15
JP2008527039A (ja) 2008-07-24
WO2006078575A3 (en) 2007-12-13
WO2006078575A2 (en) 2006-07-27
EP1855664A4 (en) 2009-12-23
EP1855664A2 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
US20080102068A1 (en) Mitotic Kinesin Inhibitors
US7629373B2 (en) Mitotic kinesin inhibitors
AU2004305069B2 (en) Mitotic kinesin inhibitors
AU2004311737A1 (en) Mitotic kinesin inhibitors
EP1831176A2 (en) Mitotic kinesin inhibitors
US7632839B2 (en) Mitotic kinesin inhibitors
US20090124641A1 (en) Mitotic Kinesin Inhibitors
WO2006086358A2 (en) Mitotic kinesin inhibitors
EP1765830B1 (en) Mitotic kinesin inhibitors
WO2006007496A2 (en) Mitotic kinesin inhibitors
CA2547746A1 (en) Mitotic kinesin inhibitors
EP1781285A2 (en) Mitotic kinesin inhibitors
WO2006023083A1 (en) Mitotic kinesin inhibitors
JP2008505090A (ja) 有糸分裂キネシン阻害剤のプロドラッグ

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application